Table 5 Frequency of HPV-positive cases (Breast cancer) by clinicopathological factors
From: Presence of human papillomavirus DNA in breast cancer: a Spanish case-control study
Number | HPV+ | HPV- | P* | OR (CI 95%) | ||||
|---|---|---|---|---|---|---|---|---|
n | % | n | % | |||||
Lymph vascular invasion | Yes | 43 | 23 | 17.7% | 20 | 16.5% | 0.868 | 1.1 (0.6–2.1) |
No | 208 | 107 | 82.3% | 101 | 83.5% | 1 | ||
Lymph node metastasis | Yes | 104 | 52 | 40.0% | 52 | 43.0% | 0.701 | 0.9 (0.5–1.5) |
No | 147 | 78 | 60.0% | 69 | 57.0% | 1 | ||
Metastasis | Yes | 10 | 6 | 4.6% | 4 | 3.3% | 0.751 | 1.4 (0.4–5.1) |
No | 241 | 124 | 95.4% | 117 | 96.7% | 1 | ||
Neoadjuvant therapy | Yes | 33 | 16 | 12.3% | 17 | 14.0% | 0.712 | 0.9 (0.4–1.8) |
No | 218 | 114 | 87.7% | 104 | 86.0% | 1 | ||
Stage | 0 | 25 | 14 | 10.9% | 11 | 9.3% | 0.724 | 1 |
IA | 51 | 30 | 23.4% | 21 | 17.8% | 1.1 (0.4–2.9) | ||
IB | 1 | 1 | 0.8% | 0 | 0.0% | … | ||
IIA | 78 | 35 | 27.3% | 43 | 36.4% | 0.6 (0.3–1.6) | ||
IIB | 45 | 25 | 19.5% | 20 | 16.9% | 1.0 (0.4–2.6) | ||
IIIA | 32 | 15 | 11.7% | 17 | 14.4% | 0.7 (0.2–2.0) | ||
IIIC | 3 | 2 | 1.6% | 1 | 0.8% | 1.6 (0.1–20.0) | ||
IV | 11 | 6 | 4.7% | 5 | 4.2% | 0.9 (0.2–3.9) | ||
ER | 0 | 39 | 18 | 14.1% | 21 | 17.5% | 0.407 | 2.6 (0.2–27.0) |
1–19% | 4 | 1 | 0.8% | 3 | 2.5% | 1 | ||
≥20% | 205 | 109 | 85.2% | 96 | 80.0% | 3.4 (0.3–33.1) | ||
PgR | 0 | 51 | 26 | 20.3% | 25 | 20.8% | 0.581 | 0.7 (0.3–1.7) |
1–19% | 37 | 22 | 17.2% | 15 | 12.5% | 1 | ||
≥20% | 160 | 80 | 62.5% | 80 | 66.7% | 0.7 (0.3–1.4) | ||
HER2 | + | 43 | 27 | 21.3% | 16 | 13.8% | 0.134 | 1.7 (0.9–3.3) |
− | 200 | 100 | 78.7% | 100 | 86.2% | 1 | ||
Ki-67 | < 14 | 84 | 37 | 28.9% | 47 | 39.5% | 0.083 | 1 |
14–19* | 71 | 44 | 34.4% | 27 | 22.7% | 2.1 (1.1–3.9) | ||
≥ 20 | 91 | 47 | 36.7% | 45 | 37.8% | 1.4 (0.7–2.5) | ||
Immunohisto-chemical subtypes | LUMINAL A | 88 | 37 | 29.4% | 51 | 44.0% | 0.055 | 1.2 (0.4–4.0) |
LUMINAL B/HER2- | 83 | 50 | 39.7% | 33 | 28.4% | 2.1 (0.6–7.1) | ||
LUMINAL B/HER2+ | 35 | 23 | 18.3% | 12 | 10.3% | 2.7 (0.7–10.4) | ||
HER2+ | 12 | 5 | 4.0% | 7 | 6.0% | 1 | ||
TRIPLE NEGATIVE | 24 | 11 | 8.7% | 13 | 11.2% | 1.2 (0.3–4.8) | ||